DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Edotreotide
Edotreotide
Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future
Multi-Discipline Review(S)
Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1
2016 Medicines in Development for Rare Diseases a LIST of ORPHAN DRUGS in the PIPELINE
First Patient in Phase III Clinical Trial COMPETE with N.C.A.177Lu-Edotreotide (Solucin®) in Cancer Patients with GEP-NET
Ongoing and Future Clinical Investigation in GEP Nens
Practical Guide to Supportive Care of Patients with Functional Neuroendocrine Tumors
Lists of Medicinal Products for Rare Diseases in Europe*
Assessment Report
Summary of Product Characteristics
Stembook 2018.Pdf
Ga]Ga-DOTA-TOC: the First FDA-Approved 68Ga-Radiopharmaceutical for PET Imaging
68Ga-NODAGA-JR11
PEPTIDES in CANCER RESEARCH Cancer Research
International Nonproprietary Names (Inn) for Biological and Biotechnological Substances
(INN) for Biological and Biotechnological Substances
Procedure Guidelines for PET/CT Tumour Imaging with Ga-DOTA
Systemic Therapy for Advanced Carcinoid Tumors: Where Do We Go from Here?
Top View
763.Full.Pdf
Targeted Systemic Treatment of Neuroendocrine Tumors: Current Options and Future Perspectives
Orphan Drug Designations and Approvals List As of 12-02-2013 Governs January 1, 2014
Pharmaceutical Appendix to the Tariff Schedule 2
GUIDELINES Ga68dota-X-Apr-26-2010
Targeted Cancer Therapy: What's New in the Field of Neuroendocrine
For Neuroendocrine Tumours No
Marketing Authorization for Tocscan® (68Ga-Edotreotide) in Germany, Austria and France
International Nonproprietary Names (Inn) for Biological and Biotechnological Substances
WO 2010/033207 Al
Targeted Systemic Treatment of Neuroendocrine Tumors: Current Options and Future Perspectives
Assessment Report
Report to NSAC of the Subcommittee on Isotopes
Future Directions in the Treatment of Neuroendocrine Tumors
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances 2009
Optimizing the Management of Gastroenteropancreatic
Orphan Drug Designations and Approvals List As of 12‐01‐2014
WO 2016/192680 Al 8 December 2016 (08.12.2016) P O P C T
Clinical History of the Theranostic Radionuclide Approach to Neuroendocrine Tumors and Other Types of Cancer: Historical Review Based on an Interview of Eric P
Systemic Treatment Selection for Patients with Advanced Pancreatic Neuroendocrine Tumours (Pannets)
Pharma Support Virtual Event Bag
L:\0900\0900PHARMAPPX .Wpd
13-16 January 2020 PRAC Meeting Minutes
Rare Diseases
Somakit TOC, INN-Edotreotide
Somatostatin Receptor Imaging of Neuroendocrine Tumors: from Agonists to Antagonists
(12) Patent Application Publication (10) Pub. No.: US 2016/0159877 A1 Retallack Et Al